Skip to main content
Top
Published in: AIDS and Behavior 3/2018

01-03-2018 | Original Paper

An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART)

Authors: John A. Sauceda, Torsten B. Neilands, Mallory O. Johnson, Parya Saberi

Published in: AIDS and Behavior | Issue 3/2018

Login to get access

Abstract

Relying on the most frequently reported barriers to adherence and convenient definitions of non-adherence may lead to less valid results. We used a dominance analysis (a regression-based approach) to identify the most important barriers to adherence based on effect size using data collected through an online survey. The survey included the Adherence Barrier Questionnaire, self-reported non-adherence defined as a 4-day treatment interruption, and HIV clinical outcomes. The sample (N = 1217) was largely male, gay identified, and White. Nearly 1 in 3 participants reported “simply forgot” as a barrier; however, in a dominance analysis, it yielded a small effect size it its association with a 4-day treatment interruption. Further, dominance analyses stratified by race/ethnicity and age suggested that not all barriers impact all groups equally. The most frequently reported barriers to adherence were not the most important, and interventions should focus on barriers more strongly linked to clinical outcomes.
Literature
1.
go back to reference Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in Adults. 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;2016(316):191–210.CrossRef Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in Adults. 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;2016(316):191–210.CrossRef
2.
go back to reference Tseng A, Seet J, Phillips EJ. The evaluation of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2014;79:182–94.CrossRef Tseng A, Seet J, Phillips EJ. The evaluation of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2014;79:182–94.CrossRef
3.
go back to reference Parienti JJ, Paterson DL. Number of missed doses: why 1 × 7 does not make 7 × 1? AIDS. 2012;26:1437–40.CrossRefPubMed Parienti JJ, Paterson DL. Number of missed doses: why 1 × 7 does not make 7 × 1? AIDS. 2012;26:1437–40.CrossRefPubMed
4.
go back to reference The Breather (Penta 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomized, open-label, non-inferiority, phase 2/3 trial. Lancet HIV. 2016;3:e421–30.CrossRef The Breather (Penta 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomized, open-label, non-inferiority, phase 2/3 trial. Lancet HIV. 2016;3:e421–30.CrossRef
5.
go back to reference Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415–23.CrossRefPubMedPubMedCentral Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415–23.CrossRefPubMedPubMedCentral
7.
go back to reference Mills EJ, Nachega JB, Bangsberg DR. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:2039–64. Mills EJ, Nachega JB, Bangsberg DR. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:2039–64.
8.
go back to reference Barfod T, Sorensen H, Nielsen H, Rodkjaer L, Obel N. “Simply forgot” is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence. HIV Med. 2006;7:285–90.CrossRefPubMed Barfod T, Sorensen H, Nielsen H, Rodkjaer L, Obel N. “Simply forgot” is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence. HIV Med. 2006;7:285–90.CrossRefPubMed
9.
go back to reference Saberi P, Neilands TB, Vittinghoff E. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS Clinical Trials Group study participants. AIDS Patient Care STDS. 2015;29:111–6.CrossRefPubMedPubMedCentral Saberi P, Neilands TB, Vittinghoff E. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS Clinical Trials Group study participants. AIDS Patient Care STDS. 2015;29:111–6.CrossRefPubMedPubMedCentral
10.
go back to reference Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral
11.
go back to reference O’Connor JL, Gardner EM, Esser SB, et al. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy. HIV Med. 2016;17:124–32.CrossRefPubMed O’Connor JL, Gardner EM, Esser SB, et al. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy. HIV Med. 2016;17:124–32.CrossRefPubMed
12.
go back to reference Haberer JE, Nicholas M, Yap Boum, et al. Duration of antiretroviral therapy adherence interruption is associated with risk of virologic rebound as determined by real-time adherence monitoring in Rural Uganda. J Acquir Immune Defic Syndr. 2015;70:386–92.CrossRefPubMedPubMedCentral Haberer JE, Nicholas M, Yap Boum, et al. Duration of antiretroviral therapy adherence interruption is associated with risk of virologic rebound as determined by real-time adherence monitoring in Rural Uganda. J Acquir Immune Defic Syndr. 2015;70:386–92.CrossRefPubMedPubMedCentral
13.
go back to reference Yuan P, Bare MG, Johnson MO, Saberi P. Using online social media for recruitment of Human Immunodeficiency Virus-positive participants: a cross-sectional survey. J Med Internet Res. 2015;16:e117.CrossRef Yuan P, Bare MG, Johnson MO, Saberi P. Using online social media for recruitment of Human Immunodeficiency Virus-positive participants: a cross-sectional survey. J Med Internet Res. 2015;16:e117.CrossRef
14.
go back to reference Kalichman SC, Rompa D, Cage M. Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STDS AIDS. 2000;11:579–85.CrossRef Kalichman SC, Rompa D, Cage M. Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STDS AIDS. 2000;11:579–85.CrossRef
15.
go back to reference Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255–66.CrossRefPubMed Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255–66.CrossRefPubMed
16.
go back to reference Saberi P, Yuan P, John M, Sheon N, Johnson MO. A pilot study to engage and counsel HIV-positive African American youth via telehealth technology. AIDS Patient Care STDS. 2013;27:529–32.CrossRefPubMedPubMedCentral Saberi P, Yuan P, John M, Sheon N, Johnson MO. A pilot study to engage and counsel HIV-positive African American youth via telehealth technology. AIDS Patient Care STDS. 2013;27:529–32.CrossRefPubMedPubMedCentral
17.
go back to reference Sauceda JA, Johnson MO, Saberi P. Nonadherence as 4-day antiretroviral therapy interruptions: do depression and race/ethnicity matter as much in the modern antiretroviral therapy era? AIDS Behav. 2016;20:2624–8.CrossRefPubMedPubMedCentral Sauceda JA, Johnson MO, Saberi P. Nonadherence as 4-day antiretroviral therapy interruptions: do depression and race/ethnicity matter as much in the modern antiretroviral therapy era? AIDS Behav. 2016;20:2624–8.CrossRefPubMedPubMedCentral
18.
go back to reference Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12:86–94.CrossRefPubMed Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12:86–94.CrossRefPubMed
19.
go back to reference Azen R, Budescu DV. The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods. 2003;8:129–48.CrossRefPubMed Azen R, Budescu DV. The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods. 2003;8:129–48.CrossRefPubMed
20.
go back to reference Budescu DV. Dominance analysis: a new approach to the problem of relative importance of predictors in multiple regression. Psychol Bull. 1993;114:542–51.CrossRef Budescu DV. Dominance analysis: a new approach to the problem of relative importance of predictors in multiple regression. Psychol Bull. 1993;114:542–51.CrossRef
21.
go back to reference Tonidandel S, LeBreton JM. Relative importance analysis: a useful supplement to regression analysis. J Bus Psychol. 2011;26:1–9.CrossRef Tonidandel S, LeBreton JM. Relative importance analysis: a useful supplement to regression analysis. J Bus Psychol. 2011;26:1–9.CrossRef
23.
go back to reference Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25:279–90.CrossRefPubMed Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25:279–90.CrossRefPubMed
24.
go back to reference Rubinstein ML, Selwyn PA. High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr. 1998;1:260–5.CrossRef Rubinstein ML, Selwyn PA. High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr. 1998;1:260–5.CrossRef
25.
go back to reference Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among Human Immunodeficiency Virus–infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.CrossRefPubMed Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among Human Immunodeficiency Virus–infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.CrossRefPubMed
26.
go back to reference Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297–307.CrossRefPubMedPubMedCentral Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297–307.CrossRefPubMedPubMedCentral
Metadata
Title
An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART)
Authors
John A. Sauceda
Torsten B. Neilands
Mallory O. Johnson
Parya Saberi
Publication date
01-03-2018
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1759-9

Other articles of this Issue 3/2018

AIDS and Behavior 3/2018 Go to the issue